TFS and OS in the entire study cohort. Probability of disease progression, as indicated by the TFS interval, including all patients with available clinical data. (A) TFS of patients with translocations (n = 32) (solid line) and without translocations (n = 60) (dashed line) detected by metaphase analysis (P < .001). (B) TFS in patients with 13q deletion as the sole abnormality observed by FISH with (n = 11) (solid line) and without (n = 32) (dashed line) additional translocations (P < .001). (C) Probability of death, as indicated by OS including all patients with (n = 31) (solid line) and without (n = 54) (dashed line) translocations (P < .001).